Novo Nordisk A/S
Novo Nordisk A/S
12/06/2021 | Press release | Distributed by Public on 12/06/2021 06:52
Current Report by Foreign Issuer (Form 6-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 6, 2021
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F [X] | Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes [ ] | No [X] |
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 6 December 2021 - On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021.
Under the programme initiated 5 November 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 11 November 2021 to 1 February 2022.
Since the announcement 29 November 2021, the following transactions have been made:
|
Number of B shares |
Average purchase price |
Transaction value, DKK |
|
| Accumulated, last announcement | 1,203,000 | 887,149,148 | |
| 29 November 2021 | 92,131 | 713.65 | 65,749,745 |
| 30 November 2021 | 105,000 | 710.04 | 74,553,988 |
| 1 December 2021 | 105,000 | 705.98 | 74,128,023 |
| 2 December 2021 | 108,697 | 701.59 | 76,260,753 |
| 3 December 2021 | 105,000 | 710.74 | 74,627,479 |
| Accumulated under the programme | 1,718,828 | 1,252,469,136 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 29,908,560 B shares of DKK 0.20 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12- month period beginning 3 February 2021. As of 3 December 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 31,155,009 B shares at an average share price of DKK 563.25 per B share equal to a transaction value of DKK 17,547,995,580.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
| Media: | ||
| Mette Kruse Danielsen | +45 3079 3883 | [email protected] |
| Michael Bachner (US) | +1 609 664 7308 | [email protected] |
| Investors: | ||
| Daniel Muusmann Bohsen | +45 3075 2175 | [email protected] |
| Ann Søndermølle Rendbæk | +45 3075 2253 | [email protected] |
| David Heiberg Landsted | +45 3077 6915 | [email protected] |
| Mark Joseph Root (US) | +1 848 213 3219 | [email protected] |
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 78 / 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: December 6, 2021 |
NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer |